Jason Norman
@jnorman.bsky.social
π€ 674
π₯ 415
π 12
Microbe host, researcher, microbiome drug developer at Vedanta Biosciences
pinned post!
Hello world. I'm a researcher at Vedanta Biosciences where we are developing defined bacterial consortia to modulate the microbiome and treat or prevent human disease. General focus areas: microbial ecology, drug discovery, IBD and infectious disease. Wordcloud via
scholargoggler.com
12 months ago
0
9
3
looking forward to
#ESCMIDGlobal
next week in Vienna. I'd love to connect and discuss developing microbiome drugs to prevent infection. Come to the Innovation Theater 12 April at 11:30!
7 months ago
1
2
2
reposted by
Jason Norman
Darren Incorvaia
8 months ago
If you're a scientist at the NIH or another HHS agency who was affected by today's RIF, I'd love to hear about the work you were doing and how important it was for our nation's health! I'm a staff writer at Fierce Biotech, and I can be reached through DM on BlueSky or securely on Signal at dinc.49
0
118
59
reposted by
Jason Norman
Wiep Klaas Smits (ExpBac/CMAT)
10 months ago
New publication: This is work stems from the mind of Quinten Ducarmon, and was led by PhD student Sam Nooij. Our group contributed to the culturing of the isolates and generating the complete genomes. What 's in this manuscript? π
www.nature.com/articles/s41...
loading . . .
Metagenomic global survey and in-depth genomic analyses of Ruminococcus gnavus reveal differences across host lifestyle and health status - Nature Communications
Here, the authors present a global meta-analysis of the human gut bacterium Ruminococcus gnavus, established an isolate collection with complete genomes and identified genetic features correlating wit...
https://www.nature.com/articles/s41467-025-56449-x
2
9
3
reposted by
Jason Norman
Bernat Olle
10 months ago
www.businesswire.com/news/home/20...
loading . . .
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today annou
https://www.businesswire.com/news/home/20250123611854/en/Vedanta-Biosciences-Publishes-Additional-Phase-2-VE303-Results-in-Nature-Medicine
0
4
1
Our team published additional results from the Phase 2 CONSORTIUM study for our rCDI candidate, VE303. This research offers new insights into PK-PD relationships and the mechanisms of action of VE303, providing a rationale for the drugβs protective effects in rCDI.
www.nature.com/articles/s41...
loading . . .
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection - Nature Medicine
Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent Clostridioides difficile infection in the context of a phase 2 trial show rob...
https://www.nature.com/articles/s41591-024-03337-4
10 months ago
0
6
2
Reposting from the other place.. I am looking to hire a Bioinformatics Scientist to join the Systems Biology team at Vedanta Biosciences, Inc. We're considering candidates local to Boston and up to 100% remote (if in the US). Please help me spread the word
job-boards.greenhouse.io/vedantabiosc...
loading . . .
Job Application for Scientist I/II, Bioinformatics at Vedanta Biosciences
https://job-boards.greenhouse.io/vedantabiosciences/jobs/7674824002
12 months ago
0
1
2
reposted by
Jason Norman
Scott Saunders
12 months ago
Wow - bluesky! π π¦ Please help me amplify a special faculty search. We're looking for someone in "Microbial Systems Biology" to join me and
@kreynoldslab.bsky.social
at UTSW Sys Bio / Bioinformatics. There is an empty lab space right next to us waiting for you!
apply.interfolio.com/154339
1/4
3
94
103
reposted by
Jason Norman
Justin Silverman
12 months ago
Nice paper by Nishijima et al, from Bork's lab using machine learning to show that the absolute bacterial load is a major confounder in most human microbiome studies (
www.cell.com/cell/fulltex...
. Now seems a good time to outline the approaches that we have been developing.
loading . . .
https://www.cell.com/cell/fulltext/S0092-8674(24)01204-2)
1
5
4
Hello world. I'm a researcher at Vedanta Biosciences where we are developing defined bacterial consortia to modulate the microbiome and treat or prevent human disease. General focus areas: microbial ecology, drug discovery, IBD and infectious disease. Wordcloud via
scholargoggler.com
12 months ago
0
9
3
reposted by
Jason Norman
Stephen Turner
12 months ago
Another lovely feature of this platform to decelerate the dunking/hot takes: if someone has quote-posted you with negative/snarky commentary, you can detach your post from their quote. You can also turn quote posts off altogether when composing a new post.
0
15
4
A great opportunity for sure ππ»
add a skeleton here at some point
12 months ago
0
1
0
reposted by
Jason Norman
Stephen Turner
about 1 year ago
A thread with some new starter packs in genomics and bioinformatics π§΅ 1/13...
8
123
64
shout out to BioRender users... NIAID created a free version
bioart.niaid.nih.gov
loading . . .
Bioart
https://bioart.niaid.nih.gov/
about 1 year ago
0
1
0
I'm looking to grow my
#microbiome
research network in the platform. Is there a way to search for starter packs? Any recommendations?
about 1 year ago
1
2
0
Feeling inspired by the
@bsky.app
growth. Might just have to get back into the social media groove. Keep posting all things science and drug dev yβall.
about 1 year ago
0
1
0
really looking forward to
#DDW2024
and to share some of the latest research from VedantaBio on the VE303 defined consortium for preventing rCDI. I'd love to connect.
over 1 year ago
0
2
0
you reached the end!!
feeds!
log in